Sleep and Circadian Mechanisms of Non-dipping Blood Pressure
Sleep and Circadian Mechanisms Contributing to Nocturnal Non-dipping Blood Pressure
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
By studying standardized behaviors and regulators of BP during sleep and behavioral stresses across all circadian phases, this protocol will allow us specifically to:
- To determine if poor sleep, while controlling for circadian phase, contributes to the higher overall BP and reduced nocturnal drop in BP in Blacks compared to Whites.
- To determine if reduced BP responses to standardized behavioral changes across the day and night contribute to the higher overall BP and reduced nocturnal drop in BP in Blacks compared to Whites.
- To determine if reduced circadian amplitude of BP contributes to the higher overall BP and reduced nocturnal drop in BP in Blacks compared to Whites.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Nicole P Bowles, PhD
- Phone Number: 5034942541
- Email: bowlesn@ohsu.edu
Study Contact Backup
- Name: Latroy Robinson, BS
- Phone Number: 5033463808
- Email: robinlat@ohsu.edu
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Study Population
Description
Inclusion Criteria:
- Self-identified Black or White
- 'normotensive' (resting systolic blood pressure (SBP) <140/90 mmHg) or uncomplicated stage 1 'hypertensive' (systolic BP between 140 and 160 mmHg or a diastolic (DBP) between 90 and 100 mmHg).
- free of all prescription and non-prescription drugs (including caffeine, nicotine, alcohol and herbal medications)
Exclusion Criteria:
- Currently treated with pharmacologic agents for hypertension
- Blood pressure >160/100 mmHg
- Smoked within the last year
- Regular night work or rotating shift work for the three months prior to the study
- Travel across more than three time zones during the three months prior to the study.
- Any acute, chronic or debilitating medical conditions, other than mild hypertension (140<SBP<160 or 90<DBP<100 mmHg) and severe renal disease (glomerular filtration rate <30)
- Moderate to severe obstructive sleep apnea (OSA)
- History of severe psychiatric illnesses or psychiatric disorders will be excluded, including alcoholism, drug dependency, major depression, manic depressive illness, schizophrenic disorders, panic disorder, generalized anxiety disorder, post-traumatic stress disorder, agoraphobia, claustrophobia, paranoid personality disorder, schizoid personality disorder, schizotypal personality disorder, borderline personality disorder, and antisocial personality disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: White Adults
White adults aged 30-60 with a BMI of 18.5<BMI<40 kg/m2 who are non-smokers (≥1 year), not on prescription medications (except oral contraceptives), and have had no recent shift work or major travel.
Mild, unmanaged hypertension (below 160/100) and renal disease are allowed.
|
Participants will complete a 7-day circadian study protocol with numerous repeated blood pressure and other cardiovascular measures across the circadian cycle.
All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
|
|
Other: Black Adults
Black adults aged 30-60 with a BMI of 18.5<BMI<40 kg/m2 who are non-smokers (≥1 year), not on prescription medications (except oral contraceptives), and have had no recent shift work or major travel.
Mild, unmanaged hypertension (below 160/100) and renal disease are allowed.
|
Participants will complete a 7-day circadian study protocol with numerous repeated blood pressure and other cardiovascular measures across the circadian cycle.
All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Nighttime Systolic Blood Pressure
Time Frame: Baseline Night Average
|
Systolic blood pressure measured via automatic sphygmomanometer every 30 minutes during sleep period at baseline.
Readings recorded in units of mmHg.
|
Baseline Night Average
|
|
Nighttime Diastolic Blood Pressure
Time Frame: Baseline Night Average
|
Diastolic blood pressure measured via automatic sphygmomanometer every 30 minutes during sleep period at baseline.
Readings recorded in units of mmHg.
|
Baseline Night Average
|
|
Daytime Systolic Blood Pressure
Time Frame: Baseline Daytime Average
|
Systolic blood pressure measured via automatic sphygmomanometer every 20 minutes during the daytime period at baseline.
Readings recorded in units of mmHg.
|
Baseline Daytime Average
|
|
Daytime Diastolic Blood Pressure
Time Frame: Baseline Daytime Average
|
Diastolic blood pressure measured via automatic sphygmomanometer every 20 minutes during the daytime period at baseline.
Readings recorded in units of mmHg.
|
Baseline Daytime Average
|
|
Change in Systolic Blood Pressure Across Sleep Period
Time Frame: 7 days in the laboratory
|
Change in systolic blood pressure per hour of scheduled sleep period measured via automatic sphygmomanometer every 30 minutes across each of the scheduled sleep periods while participants stayed 7-nights and days in the laboratory.
Sleep was scheduled to occur at varied times across the entire circadian cycle so that the effects of the circadian cycle can be ignored (i.e., averaged out).
|
7 days in the laboratory
|
|
Change in Diastolic Blood Pressure Across Sleep Period
Time Frame: 7 days in the laboratory
|
Change in diastolic blood pressure per hour of scheduled sleep period measured via automatic sphygmomanometer every 30 minutes across each of the scheduled sleep periods while participants stayed 7-nights and days in the laboratory.
Sleep was scheduled to occur at varied times across the entire circadian cycle so that the effects of the circadian cycle can be ignored (i.e., averaged out).
|
7 days in the laboratory
|
|
Circadian Amplitude of Systolic Blood Pressure When Awake
Time Frame: 7 days in the laboratory
|
Systolic blood pressure was assessed manually via sphygmomanometry during each scheduled wakefulness period while participants stayed 7-nights and days in the laboratory.
Behaviors during wakefulness were standardized and scheduled to occur across the entire circadian cycle.
Any systematic circadian rhythmicity was assessed by analysis of variance which revealed the underlying amplitude of the circadian rhythm of systolic blood pressure while controlling for (averaging out) any ongoing behaviors.
|
7 days in the laboratory
|
|
Circadian Amplitude of Diastolic Blood Pressure When Awake
Time Frame: 7 days in the laboratory
|
Diastolic blood pressure was assessed manually via sphygmomanometry during each scheduled wakefulness period while participants stayed 7-nights and days in the laboratory.
Behaviors during wakefulness were standardized and scheduled to occur across the entire circadian cycle.
Any systematic circadian rhythmicity was assessed by analysis of variance which revealed the underlying amplitude of the circadian rhythm of diastolic blood pressure while controlling for (averaging out) any ongoing behaviors.
|
7 days in the laboratory
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
venous epinephrine
Time Frame: 7-day lab stay
|
Venous epinephrine will be measured for adrenal cortex contribution to sympathetic activity.
|
7-day lab stay
|
|
venous norepinephrine
Time Frame: 7-day lab stay
|
venous norepinephrine will be measured for sympathetic nerve activity's contribution to sympathetic activity.
|
7-day lab stay
|
|
saliva cortisol
Time Frame: 7-day lab stay
|
Saliva cortisol will be measured as a sympathetic potentiating hormone.
|
7-day lab stay
|
|
saliva melatonin
Time Frame: 7-day lab stay
|
saliva melatonin will be measured as a sympathetic attenuating hormone.
|
7-day lab stay
|
|
venous aldosterone
Time Frame: 7-day lab stay
|
venous aldosterone will be measured as an end point of renin-angiotensin and sympathetic nerve activation
|
7-day lab stay
|
|
venous endocannabinoids
Time Frame: 7-day lab stay
|
venous endocannabinoids will be measured to estimate stress habituation.
|
7-day lab stay
|
|
flow mediated dilation
Time Frame: 7-day lab stay
|
Flow mediated dilation will be measured as an indication of endothelial function.
|
7-day lab stay
|
|
beat-by-beat blood pressure
Time Frame: 7-day lab stay
|
Beat-by-beat Blood Pressure will be measured in the fingers using a non-invasive blood pressure monitoring device.
|
7-day lab stay
|
|
24-hr ambulatory blood pressure
Time Frame: 2 day ambulatory period
|
Ambulatory blood pressure will be measured with an automatic 24-hr blood pressure monitoring device to estimate of blood pressure dipping status.
|
2 day ambulatory period
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Steven A Shea, PhD, Ore
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB 16803
- R35HL155681 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.